NDAORALSOLUTION
Approved
Jan 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
HICON (sodium iodide i 131) by Jubilant Therapeutics is sodium-iodide symporter (nis) protein, in thyroid follicular cells. First approved in 2003.
Drug data last refreshed 19h ago
Mechanism of Action
sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I) which in turn iodinates tyrosine residues of thyroglobulin (tri…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
Started Nov 2020
465 enrolled
Functional Bowel Disorder
A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers
Started Dec 2019
48 enrolled
Healthy
Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia
Started Jan 2017
339 enrolled
Dyspepsia
Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence
Started Jul 2005
217 enrolled
Diarrhea
Worked on HICON at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.